News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pluristem Therapeutics (PSTI) Partners With CPC Clinical Research for Peripheral Artery Disease Study


7/18/2012 9:27:01 AM

HAIFA, Israel, July 18, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites. This partnership will leverage CPC's clinical study expertise, including patient recruitment, study monitoring, pharmacovigilance, site audits, quality assurance, biostatistics, data management and medical writing.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES